Rutgers Cancer Institute Ramps up COVID-19 Hydroxychloroquine & Zithromax Trial: Following Success from France’s Méditerranée Infection

Rutgers Cancer Institute of New Jersey is participating in a COVID-19 study investigating whether azithromycin (Zithromax) combined with hydroxychloroquine (Plaquenil) is better than hydroxychloroquine alone as a possible treatment for patients diagnosed with COVID-19. The sites include Rutgers Cancer Institute, Robert Wood Johnson University Hospital in New Brunswick, and University Hospital in Newark. The clinical trial is not limited to patients with cancer.


